The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
The abundant nuclear enzyme poly(ADP‐ribose) polymerase‐1 (PARP‐1), represents an important novel target in cancer therapy. PARP‐1 is essential to the repair of DNA single‐strand breaks via the base excision repair pathway. Inhibitors of PARP‐1 have been shown to enhance the cytotoxic effects of ionizing radiation and DNA damaging chemotherapy agents, such as the methylating agents and topoisomerase I inhibitors. There are currently at least five PARP inhibitors in clinical trial development. Recent in vitro and in vivo evidence suggests that PARP inhibitors could be used not only as chemo/radiotherapy sensitizers, but as single agents to selectively kill cancers defective in DNA repair, specifically cancers with mutations in the breast cancer associated (BRCA) 1 and 2 genes. This theory of selectively exploiting cells defective in one DNA repair pathway by inhibiting another is a major breakthrough in the treatment of cancer. BRCA1/2 mutations are responsible for the majority of genetic breast/ovarian cancers, known as the hereditary breast ovarian cancer syndrome. This review summarizes the preclinical and clinical evidence for the potential of PARP inhibitors in genetic breast and ovarian cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genome maintenance mechanisms for preventing cancer
Hoeijmakers, J. H. J. (2001) · Nature · doi:10.1038/35077232 · Cited by 3,939
Risks of cancer in BRCA1-mutation carriers
FORD, D. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91578-4 · Cited by 1,850
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors
Esteller, M. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.7.564 · Cited by 1,233
Chambon, P., Weill, J. D., & Mandel, P. (1963) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(63)90024-x · Cited by 654
Association of BRCA1 with the hRad50-hMre11-p95 Complex and the DNA Damage Response
Zhong, Q., Chen, C.-F., Li, S., Chen, Y., Wang, C.-C., Xiao, J., Chen, P.-L., Sharp, Z. D., & Lee, W.-H. (1999) · Science · doi:10.1126/science.285.5428.747 · Cited by 626
Calabrese, C. R., Almassy, R., Barton, S., Batey, M. A., Calvert, A. H., Canan-Koch, S., Durkacz, B. W., Hostomsky, Z., Kumpf, R. A., Kyle, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh005 · Cited by 487
Research works printed but not linked: 45
- 10.1001/jama.279.12.922 · DOI · Paper page
- Kerlikowske K., 1992, Should women with familial ovarian cancer undergo prophylactic oophorectomy?, Obstet. Gynecol., 80, 700
- 10.1002/(SICI)1097-0215(19970529)71:5<800::AID-IJC18>3.0.CO;2-B · DOI · Paper page
- 10.1056/NEJM199704173361602 · DOI · Paper page
- 10.1086/421251 · DOI · Paper page
- 10.1126/science.1978757 · DOI · Paper page
- 10.1086/301639 · DOI · Paper page
- 10.1038/ng1837 · DOI · Paper page
- 10.1053/gast.2000.20228 · DOI · Paper page
- 10.1093/carcin/bgl062 · DOI
- 10.1002/ijc.2910640613 · DOI · Paper page
- 10.1093/jnci/94.18.1365 · DOI · Paper page
- 10.1093/jnci/91.15.1310 · DOI · Paper page
- 10.1200/JCO.2004.05.055 · DOI · Paper page
- 10.1093/jnci/djj465 · DOI · Paper page
- Levy‐Lahad E., 1997, Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast‐ovarian cancer families, Am. J. Hum. Genet., 60, 1059
- 10.1073/pnas.68.4.820 · DOI · Paper page
- 10.1126/science.7545954 · DOI · Paper page
- 10.1038/378789a0 · DOI · Paper page
- 10.1038/sj.onc.1209874 · DOI · Paper page
- 10.1038/nrg1746 · DOI · Paper page
- 10.1016/S1097-2765(02)00580-4 · DOI
- 10.1016/S1097-2765(01)00175-7 · DOI · Paper page
- 10.1016/S0092-8674(01)00209-4 · DOI
- 10.1038/sj.onc.1209881 · DOI
- 10.1074/jbc.C000276200 · DOI · Paper page
- 10.1038/sj.bjc.6600859 · DOI · Paper page
- 10.1038/nrm1963 · DOI · Paper page
- 10.1007/BF00928449 · doi:10.1007/bf00928449
- 10.1111/j.1469-185X.1990.tb01240.x · doi:10.1111/j.1469-185x.1990.tb01240.x
- 10.1093/nar/gkg703 · DOI · Paper page
- 10.1093/nar/gkl108 · DOI · Paper page
- 10.1101/gad.1331805 · DOI · Paper page
- 10.1042/bj1850775 · DOI · Paper page
- 10.1126/science.6420886 · DOI · Paper page
- Plummer R., 2005, First in human phase I trial of the PARP inhibitor AG‐014699 with Temozolomide (TMZ) in patients (pts) with advanced solid tumours, Proc. Am. Soc. Clin. Oncol., 10.1200/jco.2005.23.16_suppl.3065 · DOI
- Plummer R., 2006, First and final report of a phase II study of the poly(ADP‐ribose) polymerase (PARP) inhibitor, AG014699, in combination with Temozolomide (TMZ) in patients with metastatic malignant melanoma (MM), Proc. Am. Soc. Clin. Oncol., 10.1200/jco.2006.24.18_suppl.8013 · DOI · Paper page
- Yap T.A., 2007, First in human phase 1 pharmacokinetic and pharmacodynamic study of KU‐0059436 (Ku), a small molecule inhibitor of Poly(ADP‐ribose) polymerase (PARP) in cancer patients including BRCA1/2 mutation carriers, Proc. Am. Soc. Clin. Oncol.
- Kummar S., 2007, Inhibition of poly (ADP‐ribose) polymerase (PARP) by ABT‐888 in patients with advanced malignancies: results of a phase 0 trial, J. Clin. Oncol., 25, 3518, 10.1200/jco.2007.25.18_suppl.3518 · doi:10.1200/jco.2007.25.18_suppl.3518
- 10.1038/nature03443 · DOI · Paper page
- 10.1038/nature03445 · DOI · Paper page
- 10.1038/nrg816 · DOI · Paper page
- Baldwin R.L., 2000, BRCA1 promoter region hypermethylation in ovarian carcinoma: a population‐based study, Cancer Res., 60, 5329
- 10.1016/S0092-8674(03)00930-9 · DOI · Paper page
- 10.1200/JCO.2005.05.4171 · DOI · Paper page
Cited by
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes
Gupte, R., Liu, Z., & Kraus, W. L. (2017) · Genes & Development · doi:10.1101/gad.291518.116 · Cited by 681
“Rucaparib administered in continuous doses was shown to be effective against germline BRCAmutant cancers in stage II clinical trials (Drew and Calvert 2008; Brown et al. 2016; Drew et al. 2016).”
BackgroundThe role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2
Study, A. C. (., Song, H., The Australian Ovarian Cancer Study Group, The Ovarian Cancer Association Consortium, Ramus, S. J., Tyrer, J., Bolton, K. L., Gentry-Maharaj, A., Wozniak, E., Anton-Culver, H., et al. (2009) · Nature Genetics · doi:10.1038/ng.424 · Cited by 313
Future of Personalized Medicine in Oncology: A Systems Biology Approach
Gonzalez-Angulo, A. M., Hennessy, B. T. J., & Mills, G. B. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0777 · Cited by 261
Ishaque, N., Abba, M. L., Hauser, C., Patil, N., Paramasivam, N., Huebschmann, D., Leupold, J. H., Balasubramanian, G. P., Kleinheinz, K., Toprak, U. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07041-z · Cited by 132
Kirova, Y. M., Savignoni, A., Sigal-Zafrani, B., de La Rochefordiere, A., Salmon, R. J., This, P., Asselain, B., Stoppa-Lyonnet, D., & Fourquet, A. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0685-6 · Cited by 102
“BRCA1/2 mutations are responsible for the majority of genetic breast/ovarian cancers, known as the hereditary breast ovarian cancer syndrome [ 57 ].”
Background
Metadata
- Authors
- Drew, Y., & Calvert, H.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2008-09
- Volume
- 1138
- Issue
- 1
- Pages
- 136-145
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W1976583784
- Cited by
- 61
- References
- 7
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.